Business
Trial Results
Trial Results.
About this update from Provexis Plc
[{"type":"text","content":"\n RNS Number : 2656I Provexis PLC 09 March 2010 \n\nProvexis PLC\n \n(\"Provexis\" or the \"Company\")\n \nCompletion of Aspirin Comparison Human Trial for Fruitflow®\n \nProvexis plc (PXS.L), which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies, today announces the completion of the human trial comparing the effects of its Fruitflow® anti-thrombotic technology with aspirin. \nFruitflow® is a patented, scientifically-proven tomato extract which inhibits several pathways involved in platelet aggregation (a process which, if overstimulated can contribute to unwanted clot formation in the bloodstream), a known factor in cause of heart attack, stroke and venous thrombosis, and does so without any side effects.\nAspirin, an anti-inflammatory drug, primarily targets one specific platelet aggregation pathway, and is not recommended for use by the population at large for cardiovascular disease prevention, partly due to its well known side effects which include gastric ulceration and bleeding. In addition, a significant percentage of users show some resistance to its effects. \nThe trial was undertaken by Provexis at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen, with independent statistical analysis by BIOSS, and is the tenth placebo controlled human trial undertaken with the Fruitflow extract. The trial compared the effects of Fruitflow® and aspirin over a five hour time course. Interactions between Fruitflow® and aspirin when consumed together were also studied. 43 healthy subjects completed the trial over a 7-month period and the results are statistically significant.\nFruitflow® showed up to 30% reduction from baseline platelet aggregation in each of three different biological pathways, while a single dose of aspirin caused up to 60% reduction in a single pathway, with lesser effects on the other two. The broader antiplatelet effect of Fruitflow® reflects the Company's aim to provide a daily dietary supplement with a significant effect on blood flow, but without suppressing platelet aggregation completely.\n \nThe study also showed no negative interactions between Fruitflow® and aspirin when consumed together. \n \nThe findings are significant and serve to demonstrate the ...